Introducing Matrix3 Wound Care: A breakthrough anti-infective technology for fighting multidrug-resistant infections
Developed by Andira Pharmaceuticals, Matrix3 anti-infective technology for Wound Care is a patent pending, triple synergy silver-cannabinoid formula comprised of silver, CBC, and CBG providing three-day protection against multidrug-resistant infections, including MRSA and Pseudomonas.
“Matrix3 Wound Care is poised to offer the most convenient all-in-one solution for both patients and healthcare providers – delivering the highest possible level of protection against infection through a dramatically improved anti-infective silver technology. Our extensive R&D assures that Matrix3 will deliver markedly better protection for patients and offer the best available wound healing platform healthcare professionals can rely on,” said Dr. Dana Lambert, President & CEO, Andira Pharmaceuticals
Having a potent anti-infective technology with proven three-way synergistic action means that Matrix3 can deliver ultra-reliable protection against infection – with only microgram quantities of active ingredient. This helps ensure anti-infective protection can be achieved safely by Matrix3 Wound Care products while keeping the risk of antimicrobial resistance to a bare minimum. This is truly a new generation of health technology that leverages natural compounds to deliver safer and more effective medical solutions.
There is a tremendous need for superior wound care products that can offer convenient, safe and effective protection against multidrug-resistant infections. Matrix3 products have the potential to deliver unsurpassed protection including faster onset and improved efficacy over an extended wear time when it comes to fighting a broad spectrum of drug-resistant bacteria.
Matrix3 Technology: Mechanism of Action
Matrix3 Mechanism of Action: CBC and CBG cannabinoids work synergistically with silver nano-particles to rapidly destroy disease-causing bacteria, including those that are protected by a double cell wall (Gram-negative bacteria).
First, silver nano-particles bind to the outer bacterial cell wall, causing structural damage. Next, CBC and CBG gain entry to the bacteria through the damaged outer cell wall and proceed to target the inner bacterial membrane, causing disruption of membrane integrity. Having both the outer and inner protective layers compromised is lethal to the bacteria. Additionally, the silver nano-particles release silver ions and, with protective layers no longer intact, toxic levels of silver penetrate the bacteria, resulting in further damage to intracellular components, such as bacterial DNA. By acting together through these mechanisms, the patent-pending Matrix3 components mount a simultaneous attack on both bacterial protective layers while also directing damage inside the bacterial cells. The net result is extremely fast bacterial killing with only very small doses being required. Matrix3 is so effective that the formula meets scientific criteria for triple anti-bacterial synergy against a broad spectrum of multidrug-resistant bacteria, delivering far superior protection than silver alone. Achieving powerful efficacy with only microgram doses, Matrix3 helps to keep healthy human tissues safe and also minimizes the emergence of antimicrobial resistance – all while delivering reliable protection against infection.
Matrix3 Wound Care products are especially well-suited for addressing
All of these wound types are particularly susceptible to dangerous infections. In today’s environment, there is a growing need for next generation wound care solutions that can fight against so-called “Superbugs”.
For example, the prevalence of nasal colonization with MRSA is 1-5% in the general population but is 3-5 times higher in people who work in hospitals or other healthcare facilities. MRSA spreads readily in workplaces, community centers, fitness facilities and schools.
Wound Care market is projected to grow from USD 18.5 billion in 2022 to USD 28 billion by 2029.
Wound Care is Experiencing Significant Growth. The global wound care market was valued at USD 17.49 billion in 2021. The market is projected to grow from USD 18.51 billion in 2022 to USD 28.23 billion by 2029, exhibiting a CAGR of 6.2% during the forecast period.
Approximately 2.5% of the U.S. population was suffering from chronic wounds.
Wound Care is a Chronic and Widespread Issue. In 2021, it was estimated that approximately 2.5% of the U.S. population was suffering from chronic wounds, including diabetic foot ulcers, pressure ulcers and others.
Currently, consumers do not have access to convenient, all-in-one products for everyday wound care needs that offer protection against these dangerous types of multidrug-resistant bacteria.
Matrix3 Wound Care, Andira’s novel therapeutic strategy to address Superbug Infections involves the synergistic combination of select cannabinoids with marketed antibiotics. Our Infectious Disease Program is advancing lead candidates targeting two of the Serious Threat Superbugs recognized by the U.S. Centers for Disease Control and Prevention (C.D.C.):
• Methicillin-Resistant Staphylococcus aureus (MRSA)
• Vancomycin-Resistant Enterococcus (VRE)
Andira is a privately held health science firm delivering purposeful innovation to improve lives and address critical illness.
Andira is pioneering a new generation of therapeutics by leveraging the power of natural compounds to accelerate the delivery of urgently-needed solutions for antibiotic-resistant infections and metastatic cancer.
The firm’s novel pharmacotherapeutic platform uncovers and optimizes pharmacologic synergies between natural compounds and existing medical treatments – dramatically improving the efficacy and safety of existing therapies across multiple applications, including dermatology, hospital-acquired infection, and oncology.